Cost saving for pharma firms
PolyModels Hub, the London-based startup of Harry Christodoulou that facilitates pharmaceutical research, announced last week it has raised funding of $9 million, just days after presenting its technology at the AIChE Annual Meeting in Boston.
The Greek-born company digitizes through its software some of the experimental procedures performed by researchers during the drug development process with a “click” and applies simulation models contributing to the acceleration of their production. It now aims to double its customers, which currently include leading pharmaceutical enterprises.
This is yet another addition to the list of financing for Greek startups that claim their own share in the broader health technology sector, which remains at the center of investment interest due to the development of AI solutions.
Healthtech company funding amounted to $3.9 billion in the third quarter of 2025, according to PitchBook data, recording a slight decrease compared to the previous quarter ($4 billion). However, the numbers are still moving higher compared to last year.
“Our technology saves time and tens of millions [of dollars] for pharmaceutical companies,” Christodoulou, a chemical engineer with studies at the Aristotle University of Thessaloniki and previous experience in the modeling department of the pharmaceutical company GSK, tells Kathimerini.
“With our technology, we bring the scientist in the laboratory closer to the data scientist who simulates the experiments,” he explains, emphasizing that its technology also offers an operating system that records the processes, resulting in the need to perform similar experiments in the future.
“We are reducing the average time it takes a company to run lab experiments and factory trials by 20-30%, and our goal is to reduce this by 50%. This is important because there is now pressure and competition from pharmaceutical companies to produce drugs as quickly as possible. Look at what is happening with anti-obesity drugs.”
Its software is already used by five of the top 20 pharmaceutical companies, while its technologies have already reduced the volume of drug development experiments by over 90%.
